Research Analysts Offer Predictions for DAWN Q1 Earnings

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Wedbush decreased their Q1 2025 EPS estimates for Day One Biopharmaceuticals in a report issued on Monday, April 21st. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of ($0.45) for the quarter, down from their prior forecast of ($0.43). Wedbush has a "Outperform" rating and a $32.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals' current full-year earnings is ($0.72) per share. Wedbush also issued estimates for Day One Biopharmaceuticals' Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.73) EPS, FY2026 earnings at ($1.77) EPS, FY2027 earnings at ($1.20) EPS, FY2028 earnings at ($0.09) EPS and FY2029 earnings at $0.86 EPS.

DAWN has been the topic of several other research reports. The Goldman Sachs Group cut their price target on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating on the stock in a report on Tuesday, March 25th. Bank of America reduced their target price on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. Needham & Company LLC reaffirmed a "buy" rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. JPMorgan Chase & Co. cut their price objective on Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating on the stock in a research report on Wednesday, March 5th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $36.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, April 3rd. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Day One Biopharmaceuticals has an average rating of "Buy" and an average target price of $32.29.

Day One Biopharmaceuticals Price Performance

NASDAQ DAWN opened at $7.33 on Wednesday. Day One Biopharmaceuticals has a 1-year low of $6.41 and a 1-year high of $18.07. The firm has a market capitalization of $742.92 million, a P/E ratio of -7.12 and a beta of -1.24. The business's 50-day simple moving average is $8.62 and its 200-day simple moving average is $11.71.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.34). The company had revenue of $29.21 million during the quarter, compared to analysts' expectations of $27.11 million.

Institutional Trading of Day One Biopharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new position in shares of Day One Biopharmaceuticals in the 4th quarter worth approximately $27,000. R Squared Ltd acquired a new position in Day One Biopharmaceuticals in the fourth quarter worth $31,000. Pallas Capital Advisors LLC bought a new stake in Day One Biopharmaceuticals during the first quarter valued at $87,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Day One Biopharmaceuticals during the first quarter worth $88,000. Finally, Exchange Traded Concepts LLC lifted its position in shares of Day One Biopharmaceuticals by 19.6% in the 1st quarter. Exchange Traded Concepts LLC now owns 14,693 shares of the company's stock worth $117,000 after buying an additional 2,407 shares during the last quarter. 87.95% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CFO Charles N. York II sold 4,370 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $52,265.20. Following the completion of the sale, the chief financial officer now owns 252,638 shares of the company's stock, valued at approximately $3,021,550.48. The trade was a 1.70 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Adam Dubow sold 4,646 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $55,566.16. Following the completion of the sale, the general counsel now owns 39,602 shares in the company, valued at approximately $473,639.92. This trade represents a 10.50 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 21,064 shares of company stock worth $251,925. 8.40% of the stock is currently owned by corporate insiders.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.